Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | GALR1 | P47211 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498605 | 0.98 | LTA4H (0.43) | LTA4HHPGDKDM4EMEN1MAPT | |
| SCHEMBL497607 | 0.87 | — | — | |
| SCHEMBL5746764 | 0.80 | NPC1 (0.39) | LTA4HHPGDKDM4EMEN1MAPT | |
| SCHEMBL667254 | 0.73 | KDM4E (0.43) | LTA4HHPGDKDM4EMEN1MAPT | |
| SCHEMBL16291133 | 0.73 | L3MBTL1 (0.57) | LTA4HHPGDKDM4EMEN1MAPT | |
| SCHEMBL3545 | 0.73 | L3MBTL1 (0.57) | LTA4HHPGDKDM4EMEN1MAPT | |
| Fluoride SCHEMBL491501 | 0.70 | L3MBTL1 (0.55) | LTA4HHPGDKDM4EMEN1MAPT | |
| Hydrogen Sulfide SCHEMBL22588115 | 0.70 | L3MBTL1 (0.55) | LTA4HHPGDKDM4EMEN1MAPT | |
| Ammonia Solution, Strong SCHEMBL34467257 | 0.70 | L3MBTL1 (0.55) | LTA4HHPGDKDM4EMEN1MAPT | |
| Benzene SCHEMBL28420098 | 0.70 | L3MBTL1 (0.55) | LTA4HHPGDKDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6107495-A | REACTING SPECIFIED 1-(2- OR 3-THIENYL) CYCLOHEXANES WITH A 1,5-DIHALOPENTANE TO FORM CYCLIC (THIENYLCYCLOHEXYL)AMINES SUCH AS 2-ALKYL-(3-THIENYL)CYCLOHEXYL PIPERIDINE; USE AS INTERMEDIATES TO RADIOACTIVE LABELLED MOLECULES | SOCIETE D'EXPANSION SCIENTIFIQUE EXPANSIA (FR) | 2000-08-22 | — | — | US | claimed |
| CN-110072862-B | Bicyclic nitrogen-containing heterocyclic derivative and pharmaceutical composition containing the same | 盐野义制药株式会社 | 2022-05-13 | — | — | CN | disclosed |
| CN-108834415-B | Substituted tricyclic 1, 4-benzodiazepine derivatives as allosteric modulators of group II metabotropic glutamate receptors | 多曼治疗学公司 | 2021-12-24 | — | — | CN | disclosed |
| CN-110769830-A | Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors | 马瓦隆治疗有限公司 | 2020-02-07 | — | — | CN | disclosed |
| CN-103827215-B | Iron content (II) complex and condensation catalyst, prepare the method for this catalyst and the compositions containing this catalyst | 道康宁公司 | 2016-12-21 | — | — | CN | disclosed |
| CN-101688245-B | Methods for diagnosing ischemia | UNIV CALIFORNIA | 2013-09-25 | — | — | CN | disclosed |
| US-8518975-B2 | Gamma secretase modulators | Merck Sharp + Dohme Corp. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1719768-B1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2012-04-25 | — | — | EP | disclosed |
| CN-101188942-B | Adult pancreatic derived stromal cells | LIFESCAN, INC. (US) | 2011-11-30 | — | — | CN | disclosed |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-04-07 | — | — | US | disclosed |
| CN-1009197-B | Process for preparing N, 3-disubstituted 2-oxindole-1-carboxamides | PFIZER (US) | 1990-08-15 | — | — | CN | disclosed |
| US-4859736-A | Synthetic polystyrene resin and its use in solid phase peptide synthesis | CIBA-GEIGY CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| CN-1003855-B | Process for preparing 1, 3-disubstituted 2-oxindoles | 美国辉瑞有限公司 | 1989-04-12 | — | — | CN | disclosed |
| EP-0285562-A2 | Synthetic resin | CIBA-GEIGY AG (CH) | 1988-10-05 | — | — | EP | disclosed |
| US-4721712-A | 1,3-disubstituted 2-oxindoles as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1988-01-26 | — | — | US | disclosed |
| US-4658037-A | RHEUMATIC DISEASES | PFIZER INC. (US) | 1987-04-14 | — | — | US | disclosed |
| CN-85101795-A | With 1, the two 2-oxyindoles that replace of 3-prepare pain killer and antiphlogistic | — | 1987-04-08 | — | — | CN | disclosed |
| CN-85103527-A | Preparation N, the method for the disubstituted 2-hydroxyindole of 3--1-hydroxyalkyl cooh amide | — | 1987-01-28 | — | — | CN | disclosed |
| US-4569942-A | N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents | PFIZER INC. (US) | 1986-02-11 | — | — | US | disclosed |
| US-4369179-A | TREATMENT OF DIABETES AND GASTROINTESTINAL BLEEDING WITH SOMATOSTATIN DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1983-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | LTA4H 910/4885HPGD 1744/4885KDM4E 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.